Former Head of Worldwide Development for Roche Labs To Advise HTDS
SHENZHEN, China, Nov. 23 /PRNewswire-FirstCall/ - HTDS www.htdsmedical.com Hard to Treat Diseases, Inc. (HTDS) announced appointment of Fred Carlini, former Head of Worldwide Development for Roche Labs division of Hoffman LaRoche as a strategic advisor to HTDS.
"We are delighted to attract someone of Mr. Carlini's international stature to our team at a time when we are expanding worldwide," said Carol Robichaud, Secretary of HTDS. "We are confidant that he will be instrumental not only in our rapid roll-out of our H1N1 vaccine, but in getting our products certified and guiding our manufacturing practices. We will also draw on his expertise and knowledge for our recently announced stem cell merger and launch project. More updates and some positive strides made on our stem cell project ambitions will be released shortly"
Mr. Carlini is currently President of THE S.M.A.R.T. GROUP, consulting with companies to assist in developing business plans for the healthcare market, negotiating major contracts, and aligning them with key strategic partners that compliment their business models. Mr. Carlini was one of three co-founders of LearnWright, LLC, a world-class e-learning solutions company that developed online training courseware for the international pharmaceutical industry, clinical laboratories, and blood and plasma industry on Good Manufacturing Practices (GMP), Good Clinical Practices (GCP), and Good Laboratory Practices (GLP). This online training enhanced the understanding of quality control and quality assurance with the "gold standard" of quality production in the United States, Canada, and the European Union.
HTDS has two subsidiaries, Slavica Bio Chem Co and China Mellow Hope Inc. www.mellowhope.com. Slaivca's primary focus involves the enhancement and modification of existing approved drugs such as "Virazole" for the purpose of chemical repair of damage to the CNS (central nervous system), MS (Multiple Sclerosis), SARS, Hepatis C. Mellow Hope is China-based and is the biggest exporter of Biological Vaccines in China. It has a product line that encompasses vaccines for influenza, tetanus, diphtheria and other diseases; Blood based products including human rabies immunoglobulin; and active pharmaceutical ingredient (or APIs) for injection such as celestat in.
To receive future updates via email, including quarterly newsletters and company updates that may not be newsworthy, however important to the reader and followers of the company, please sign up today at www.minamargroup.com/updates.
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only, please contact [email protected]; For any corporate matters, please contact www.minamargroup.com/helpdesk
SOURCE Hard to Treat Diseases
SHENZHEN, China, Nov. 23 /PRNewswire-FirstCall/ - HTDS www.htdsmedical.com Hard to Treat Diseases, Inc. (HTDS) announced appointment of Fred Carlini, former Head of Worldwide Development for Roche Labs division of Hoffman LaRoche as a strategic advisor to HTDS.
Advertisement
"We are delighted to attract someone of Mr. Carlini's international stature to our team at a time when we are expanding worldwide," said Carol Robichaud, Secretary of HTDS. "We are confidant that he will be instrumental not only in our rapid roll-out of our H1N1 vaccine, but in getting our products certified and guiding our manufacturing practices. We will also draw on his expertise and knowledge for our recently announced stem cell merger and launch project. More updates and some positive strides made on our stem cell project ambitions will be released shortly"
Advertisement
Mr. Carlini is currently President of THE S.M.A.R.T. GROUP, consulting with companies to assist in developing business plans for the healthcare market, negotiating major contracts, and aligning them with key strategic partners that compliment their business models. Mr. Carlini was one of three co-founders of LearnWright, LLC, a world-class e-learning solutions company that developed online training courseware for the international pharmaceutical industry, clinical laboratories, and blood and plasma industry on Good Manufacturing Practices (GMP), Good Clinical Practices (GCP), and Good Laboratory Practices (GLP). This online training enhanced the understanding of quality control and quality assurance with the "gold standard" of quality production in the United States, Canada, and the European Union.
HTDS has two subsidiaries, Slavica Bio Chem Co and China Mellow Hope Inc. www.mellowhope.com. Slaivca's primary focus involves the enhancement and modification of existing approved drugs such as "Virazole" for the purpose of chemical repair of damage to the CNS (central nervous system), MS (Multiple Sclerosis), SARS, Hepatis C. Mellow Hope is China-based and is the biggest exporter of Biological Vaccines in China. It has a product line that encompasses vaccines for influenza, tetanus, diphtheria and other diseases; Blood based products including human rabies immunoglobulin; and active pharmaceutical ingredient (or APIs) for injection such as celestat in.
To receive future updates via email, including quarterly newsletters and company updates that may not be newsworthy, however important to the reader and followers of the company, please sign up today at www.minamargroup.com/updates.
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only, please contact [email protected]; For any corporate matters, please contact www.minamargroup.com/helpdesk
SOURCE Hard to Treat Diseases
